Stem cell-based therapy for COVID-19

Xiaomei Chen; Bowen Liu; Chao Li; Yulian Wang; Suxia Geng; Xin Du; Jianyu Weng; Peilong Lai

doi:10.1016/j.intimp.2023.110890

Stem cell-based therapy for COVID-19

Int Immunopharmacol. 2023 Nov;124(Pt A):110890. doi: 10.1016/j.intimp.2023.110890. Epub 2023 Sep 7.

Authors

Xiaomei Chen¹, Bowen Liu¹, Chao Li¹, Yulian Wang¹, Suxia Geng¹, Xin Du¹, Jianyu Weng¹, Peilong Lai²

Affiliations

¹ Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, PR China.
² Department of Hematology, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong 510080, PR China. Electronic address: lai_peilong@163.com.

PMID: 37688914
DOI: 10.1016/j.intimp.2023.110890

Abstract

While The World Health Organization (WHO) has announced that COVID-19 is no longer a public health emergency of international concern(PHEIC), the risk of reinfection and new emerging variants still makes it crucial to study and work towards the prevention of COVID-19. Stem cell and stem cell-like derivatives have shown some promising results in clinical trials and preclinical studies as an alternative treatment option for the pulmonary illnesses caused by the COVID-19 and can be used as a potential vaccine. In this review, we will systematically summarize the pathophysiological process and potential mechanisms underlying stem cell-based therapy in COVID-19, and the registered COVID-19 clinical trials, and engineered extracellular vesicle as a potential vaccine for preventing COVID-19.

Keywords: COVID-19; Cell-based therapy; Clinical trials; Extracellular vesicle; Mesenchymal stem cells; Vaccines.

Publication types

Review